79 results
Keyword sustiva Remove keyword
-
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 October 2015
European Medicines Agency, London, UK, from 19/10/2015 to 22/10/2015, Last updated: 03/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2014
European Medicines Agency, London, UK, from 10/06/2014 to 13/06/2014, Last updated: 13/08/2013 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 May 2014
European Medicines Agency, London, UK, from 19/05/2014 to 22/05/2014, Last updated: 09/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 May 2014
European Medicines Agency, London, UK, from 05/05/2014 to 08/05/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 March 2015
European Medicines Agency, London, UK, from 09/03/2015 to 12/03/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2013
European Medicines Agency, London, UK, from 13/05/2013 to 16/05/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2017
European Medicines Agency, London, UK, from 27/11/2017 to 30/11/2017, Last updated: 27/11/2017 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 July 2014
European Medicines Agency, London, UK, from 07/07/2014 to 10/07/2014, Last updated: 13/08/2013 -
List item
Press release: Committee for Proprietary Medicinal Products (CPMP) 50th plenary meeting
Last updated: 25/06/1999marketing authorisations for: - Sustiva/Stocrin (efavirenz), indicated for … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 October 2015
European Medicines Agency, London, UK, from 05/10/2015 to 08/10/2015, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 October 2014
European Medicines Agency, London, UK, from 20/10/2014 to 23/10/2014, Last updated: 09/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 July 2018
European Medicines Agency, London, UK, from 09/07/2018 to 12/07/2018, Last updated: 13/03/2014 -
List item
PRAC: meeting archive 2012-2014
Last updated: 13/05/2016 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 February 2015
European Medicines Agency, London, UK, from 23/02/2015 to 26/02/2015, Last updated: 03/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 July 2014
European Medicines Agency, London, UK, from 21/07/2014 to 24/07/2014, Last updated: 09/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 October 2017
European Medicines Agency, London, UK, from 23/10/2017 to 26/10/2017, Last updated: 13/03/2014 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,21-24 May 2007
CHMP, Last updated: 25/05/2007concurrent administration of Sustiva (efavirenz), from Bristol … adjustments agreed by the CHMP. Sustiva and Stocrin are currently … -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 18-21 April 2017
European Medicines Agency, London, UK, from 18/04/2017 to 21/04/2017, Last updated: 06/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 30 November-3 December 2015
European Medicines Agency, London, UK, from 30/11/2015 to 03/12/2015, Last updated: 13/03/2014 -
List item
PRAC recommendations on safety signals: monthly overviews: Archive
Last updated: 30/05/2017 -
List item
Annual reports and work programmes (updated)
Last updated: 15/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2016
European Medicines Agency, London, UK, from 08/02/2016 to 11/02/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 24-27 October 2016
European Medicines Agency, London, UK, from 24/10/2016 to 27/10/2016, Last updated: 13/03/2014